Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $55.40.

Separately, Oppenheimer lowered their price objective on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research report on Friday, August 14th.

Pelthos Therapeutics Price Performance

Shares of PTHS stock opened at $20.92 on Wednesday. Pelthos Therapeutics has a 52 week low of $18.19 and a 52 week high of $37.50. The stock has a market capitalization of $80.12 million, a PE ratio of -0.96 and a beta of 3.01. The company has a debt-to-equity ratio of 3.40, a quick ratio of 1.31 and a current ratio of 1.98. The stock’s fifty day moving average is $25.25 and its 200-day moving average is $25.31.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($6.62) earnings per share (EPS) for the quarter. The business had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. Equities research analysts expect that Pelthos Therapeutics will post -15.22 EPS for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

An institutional investor recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr raised its position in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 9.3% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 21,073 shares of the company’s stock after buying an additional 1,792 shares during the period. Knott David M Jr owned about 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent filing with the SEC. 77.96% of the stock is currently owned by institutional investors and hedge funds.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).